Luis Rodriguez Colon, MD
General Practice · Winter Haven, FLNPI 1730417312
Payments from drug & device makers
Across 44 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$124
- Lilly USA, LLC$110
- Dexcom, Inc.$91
- GSK$72
- Pfizer$72
- Merck$58
- plus $264 from 10 others
What the payments were for
- Food & beverage$791100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 7 | $124 |
| Lilly USA, LLC | 7 | $110 |
| Dexcom, Inc. | 4 | $91 |
| GSK | 5 | $72 |
| Pfizer | 4 | $72 |
| Merck | 3 | $58 |
| Novo Nordisk | 3 | $57 |
| Mylan Specialty L.p. | 3 | $50 |
| Shield Therapeutics Inc | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Abbott | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Bayer | 1 | $17 |
| AstraZeneca | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
How this compares
$791 in reported general payments places this provider in the 70th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $122,113 |
| JardianceEmpagliflozin | 56 | $73,126 |
| XareltoRivaroxaban | 55 | $67,582 |
| EntrestoSacubitril/Valsartan | 45 | $56,012 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 58 | $40,958 |
| TrulicityDulaglutide | 19 | $29,417 |
| OzempicSemaglutide | 15 | $20,127 |
| JanuviaSitagliptin Phosphate | 16 | $19,753 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $18,078 |
| FarxigaDapagliflozin Propanediol | 18 | $17,395 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $15,905 |
| TradjentaLinagliptin | 11 | $14,410 |
| Novolin 70-30Insulin Nph Hum/Reg Insulin Hm | 43 | $11,459 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $10,281 |
| Atorvastatin Calcium | 1,105 | $10,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta | $124 | $128,493125 claims |
| PfizerEliquis | $72 | $122,113105 claims |
| AstraZenecaFarxiga, Symbicort | $17 | $33,30150 claims |
| Lilly USA, LLCTrulicity, Humulin 70-30 | $110 | $32,89845 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $72 | $28,35929 claims |
| Novo NordiskOzempic, Novolog | $57 | $23,38829 claims |
| MerckJanuvia | $58 | $19,75316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,901 general practice providers in Florida.
Other general practice in Winter Haven
- Jose CardonaMiami$71M
- Lawrence GalitzMiami Gardens$42.5M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Frank AlvarezHialeah$13.6M
- Hector RodriguezMiami$12.8M
- Eddie ArmasSouth Miami$12.4M
- Idalia AcostaMiami$11.4M
- Lilia Rodriguez AblesMiami$10.7M
- Jorge Monroy AvellaOcoee$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.